Moloney Securities Asset Management LLC Trims Stake in Danaher Co. (NYSE:DHR)

Moloney Securities Asset Management LLC lowered its holdings in shares of Danaher Co. (NYSE:DHR) by 12.5% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,785 shares of the conglomerate’s stock after selling 255 shares during the period. Moloney Securities Asset Management LLC’s holdings in Danaher were worth $446,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also bought and sold shares of DHR. Cape Investment Advisory Inc. purchased a new stake in Danaher during the 4th quarter valued at $25,000. Tsfg LLC lifted its stake in Danaher by 733.3% during the 1st quarter. Tsfg LLC now owns 100 shares of the conglomerate’s stock valued at $25,000 after acquiring an additional 88 shares during the period. CarsonAllaria Wealth Management Ltd. purchased a new stake in shares of Danaher during the 2nd quarter valued at about $25,000. Redmont Wealth Advisors LLC bought a new stake in shares of Danaher in the first quarter worth approximately $30,000. Finally, Richardson Financial Services Inc. purchased a new position in shares of Danaher during the fourth quarter valued at approximately $42,000. Hedge funds and other institutional investors own 79.05% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts have weighed in on DHR shares. Jefferies Financial Group initiated coverage on Danaher in a report on Monday, June 3rd. They issued a “buy” rating and a $295.00 target price on the stock. Wells Fargo & Company assumed coverage on shares of Danaher in a research report on Tuesday, August 27th. They set an “equal weight” rating and a $280.00 target price for the company. Bank of America increased their price target on shares of Danaher from $270.00 to $275.00 and gave the stock a “neutral” rating in a research report on Wednesday, July 24th. Royal Bank of Canada upped their price objective on Danaher from $297.00 to $300.00 and gave the stock an “outperform” rating in a research note on Wednesday, July 24th. Finally, Leerink Partners boosted their price target on Danaher from $275.00 to $280.00 and gave the company an “outperform” rating in a report on Wednesday, July 24th. Seven investment analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $278.94.

Danaher Trading Up 0.9 %

Danaher stock opened at $269.31 on Friday. The company has a debt-to-equity ratio of 0.33, a current ratio of 1.43 and a quick ratio of 1.04. The firm’s 50 day moving average price is $260.05 and its 200-day moving average price is $255.10. Danaher Co. has a 1 year low of $182.09 and a 1 year high of $281.70. The stock has a market cap of $199.47 billion, a P/E ratio of 45.65, a PEG ratio of 4.62 and a beta of 0.83.

Danaher (NYSE:DHR) last announced its quarterly earnings results on Tuesday, July 23rd. The conglomerate reported $1.72 EPS for the quarter, topping the consensus estimate of $1.57 by $0.15. The business had revenue of $5.74 billion for the quarter, compared to analysts’ expectations of $5.59 billion. Danaher had a net margin of 16.94% and a return on equity of 11.06%. The business’s quarterly revenue was down 2.9% compared to the same quarter last year. During the same quarter in the previous year, the company earned $2.05 EPS. On average, equities analysts predict that Danaher Co. will post 7.59 earnings per share for the current fiscal year.

Insider Activity at Danaher

In other news, SVP Brian W. Ellis sold 9,600 shares of the company’s stock in a transaction that occurred on Thursday, July 25th. The stock was sold at an average price of $275.16, for a total transaction of $2,641,536.00. Following the sale, the senior vice president now directly owns 20,230 shares of the company’s stock, valued at approximately $5,566,486.80. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other news, SVP Brian W. Ellis sold 9,600 shares of the business’s stock in a transaction dated Thursday, July 25th. The shares were sold at an average price of $275.16, for a total value of $2,641,536.00. Following the sale, the senior vice president now directly owns 20,230 shares in the company, valued at approximately $5,566,486.80. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Rainer Blair sold 9,007 shares of the stock in a transaction dated Wednesday, July 31st. The shares were sold at an average price of $280.00, for a total transaction of $2,521,960.00. Following the completion of the transaction, the chief executive officer now directly owns 97,983 shares of the company’s stock, valued at approximately $27,435,240. The disclosure for this sale can be found here. Over the last three months, insiders sold 39,659 shares of company stock valued at $11,042,433. Insiders own 11.10% of the company’s stock.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.